Rosacea

Journey Medical Corporation and Dr. Reddy’s Laboratories Ltd. have joined forces for the development and commercialization of DFD-19 as a treatment for rosacea.

Dermoscopy cannot diagnose D folliculorum proliferation but can reveal specific findings in patients with papulopustular rosacea.

Emmy Graber, MD, presented the updates in acne and rosacea treatments at the SCALE Acne and Rosacea update on June 9, 2021.

Nonprescription moisturizers and cleansers can play an integral role in delivering positive treatment outcomes for patients with rosacea.

Recent therapeutic advances in topical and systemic therapy offer new options for cases that have not responded to established treatment approaches.

In treatments addressing muscular contraction, botulinum toxin inhibits nerves that innervate blood vessels from releasing acetylcholine, which triggers vasodilation. Its impact on the innate immune system suggests that botulinum toxin may also help reduce recalcitrant rosacea-related papules and pustules.

New treatments continue to expand therapy options, but a cure remains elusive.

Findings from a recent study indirectly support therapeutic approaches aimed at restoring the dermal matrix.

This formulation could be first FDA-approved single-agent E-BPO prescription drug to treat rosacea.

Recent research shows prolonged face-mask usage leads to negative quality-of-life impact and worsening of disease for rosacea.

Update tracks trending factors changing the treatment landscape.

Patients with rosacea can get better results by supplementing standard minocycline oral therapy with γ-linolenic acid (GLA), according to findings from a recent study.

Experts are recommending combination therapies as a way to treat rosacea, according to a presentation at ODAC Dermatology, Aesthetic and Surgical Conference 2021 Pre-Conference Sneak Peek Inflammatory Diseases Virtual Symposium.

One expert says the action of demodex folliculorum and the composition of the symbiotic microbiota in the skin of patients with rosacea may provide valuable insights into the pathogenesis and pathophysiology of this widespread skin disease.

According to a study conducted by Galderma, both rosacea and psoriasis have a significant QOL impact on patients, with a proportion of patients reporting feelings of anxiety and depression due to their disease.

Several studies present data that contradicts one another when examining the possible link between rosacea development and smoking.

Recent literature shows associations between rosacea and numerous inflammatory gastrointestinal disorders.

Fluorescence-advanced videodermatoscopy (FAV, Adamo Srl) for characterization of Demodex mites suggests that it can be a useful tool in the clinical evaluation and management of patients with Demodex-related skin diseases.

Investigators assessed results combining oxymetazoline and four different lasers in a recent phase 4 study. Results demonstrate improvement from baseline in Clinician Erythema Assessment (CEA) score.

A variety of new vehicles designed to improve tolerability and cosmetic acceptability are providing rosacea patients with multiple viable treatment options.

A new artificial intelligence-powered diagnostic tool, Ros-NET, was able to accurately identify rosacea, making way for further development of the technology to aid in diagnosis of the skin condition, according to a recent study.

A recent study conducted by the National Rosacea Society reveals more rosacea patients are satisfied with their treatment, but highlights the need for treatment option awareness among older patient populations.

Treatment with a pulsed dye laser followed immediately by intradermal botulinumtoxinA injections appears safe and improved erythema, flushing, burning and pruritus, according to a recent study.

The 21-member global ROSacea Consensus panel developed updated recommendations for rosacea, diagnosis, classification and management to support and promote transition to a phenotype approach in rosacea.

The idea that rosacea is uncommon in darker skinned individuals may be due to under-recognition. Careful clinical examination, a thorough history and biopsy in some cases are needed for accurate diagnosis and differentiating rosacea from diseases that may be more common.

ZILXI (FMX103, VYNE Therapeutics), a 1.5% topical minocycline foam, is now available for prescription for the treatment of inflammatory lesions of rosacea in adult patients.

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.

Many patients with rosacea have features that overlap more than one subtype of the condition. A recent publication serves as a compliment to the classification guide with the intention of guiding treatment and management options based on individual patient features.

Effects of a specialized skincare regimen for sensitive and redness-prone skin were investigated in an eight-week, prospective, controlled clinical trial enrolling 60 patients with rosacea. The intervention was associated with improvements in objectively measured erythema, rosacea symptoms, and health-related quality of life.

Experts offer insights into the inflammatory pathways involved in rosacea pathogenesis, the putative anti-inflammatory mechanisms of action of treatments for rosacea, and future therapeutic needs.